Luis Rico | Oncology | Editorial Board Member

Dr. Luis Rico | Oncology | Editorial Board Member

Managing Director | Hospital Aleman | Argentina

Dr. Luis Rico is a distinguished clinician–researcher at Hospital Alemán, Buenos Aires, renowned for his impactful contributions to urology, with a strong focus on endourology, advanced laser technologies, and minimally invasive surgical innovation. His work centers on improving procedural precision, optimizing perioperative outcomes, and enhancing patient safety in the management of complex urolithiasis. By integrating next-generation laser systems, cutting-edge endoscopic platforms, and refined surgical protocols, Dr. Rico continually advances evidence-based approaches that elevate standards of clinical care. With an active and growing academic footprint, he has authored numerous peer-reviewed publications addressing pivotal challenges in intrarenal surgery, flexible ureteroscopy, and comparative laser performance particularly evaluating modalities such as the Thulium Fiber Laser and HO:YAG systems. His research has expanded global understanding of operative efficiency, stone-free rates, laser–tissue dynamics, and postoperative recovery pathways. Dr. Rico collaborates extensively with international urology organizations, multidisciplinary surgical teams, and multicenter research networks, underscoring his commitment to shared scientific progress, surgical innovation, and clinical excellence. In addition to his research, he plays a key role in clinical training, contributes to multicenter trials, and advances patient-centered care through methodical, outcomes-driven practice. His scholarly contributions reflect a balanced blend of innovation, scientific rigor, and translational relevance, ensuring continued impact on the evolving landscape of urologic surgery and minimally invasive therapeutic strategies. Dr. Rico’s academic influence is further highlighted by his research metrics, which include 252 citations, 35 scientific documents, and an h-index of 9, reflecting both the quality and reach of his contributions to modern urological science.

Featured Publications

Rico, L., Blas, L., Álvarez Jaramillo, J., Filgueira, G., Soldano, J., & Contreras, P. (2025). Magneto Ho:YAG laser versus Thulium Fiber Laser for laser lithotripsy during flexible ureteroscopy with a flexible and navigable ureteral access sheath. International Urology and Nephrology.

Rico, L., Blas, L., Banda Ramos, L., Maqueda, M., Pizzarello, J., & Contreras, P. (2025). Thulium Fiber Laser versus Vapor Tunnel HO:YAG laser in retrograde intrarenal surgery: Which one has better laser ablation performance? World Journal of Urology.

Rico, L., Diaz-Zorita, V., Blas, L., Banda Ramos, L., Sabeh, P., & Contreras, P. (2025). Is the ablation stone efficacy and efficiency better with a flexible and navigable suction ureteric access sheath? World Journal of Urology.

Rico, L., Blas, L., Pizzarello, J., Banda-Ramos, L., & Contreras, P. (2024). Mini-endoscopic combined intrarenal surgery (mini-ECIRS) for complex urolithiasis. World Journal of Urology.

Rico, L., Maqueda, M., Blas, L., & Contreras, P. (2024). Anterograde placement of drug-coated balloon for ureteroileal anastomosis stricture. BMJ Case Reports.

Shahanavaj Khan | Cancer Science | Editorial Board Member

Assoc. Prof. Dr. Shahanavaj Khan | Cancer Science | Editorial Board Member

Associate Professor | Shri Ram College | India

Dr. Shahanavaj Khan is a distinguished researcher at King Saud University, Riyadh, specializing in cancer biology, pharmacology, and bioactive natural compounds. His work focuses on the anti-cancer and anti-inflammatory potential of plant-derived molecules, with particular emphasis on mechanisms involving apoptosis, Toll-Like Receptors, and microbiome-mediated cancer pathways. Dr. Khan employs advanced in-silico, in-vitro, and translational approaches to identify novel therapeutic targets and understand disease mechanisms, aiming to improve cancer diagnostics and treatment strategies. He has authored 54 publications in high-impact journals, contributing significantly to the understanding of prostate, lung, and other cancers, while integrating computational modeling with experimental validation. His research involves extensive collaborations with over 200 co-authors globally, demonstrating leadership in multidisciplinary oncology and pharmacology networks. Through his innovative studies on natural bioactive compounds and cancer therapeutics, Dr. Khan has contributed to the advancement of safer, more targeted treatment options, positively impacting patient care and public health. His scholarly work also underscores the importance of microbiome and receptor-mediated mechanisms in disease progression, bridging fundamental research with clinical applications. Dr. Khan’s academic influence and research productivity are reflected in his metrics 1,355 citations, 54 documents, and an h-index of 21.

Profiles: Scopus

Featured Publications

Khan, S., et al. (2025). Implication of Toll-Like Receptors in growth and management of health and diseases: Special focus as a promising druggable target to Prostate Cancer. [Review]. 7 citations.

Khan, S., et al. (2025). The implication of microbiome in lungs cancer: mechanisms and strategies of cancer growth, diagnosis and therapy. [Review]. 6 citations.

Khan, S., et al. (2025). Analysis of anti-cancer and anti-inflammatory activity in Typhonium flagelliforme rhizome extract by induction of apoptosis: An in-vitro study. Fitoterapia.

Dr Ghanshyam Ghelani | Bladder Cancer | Best Researcher Award

Dr Ghanshyam Ghelani | Bladder Cancer | Best Researcher Award

SUNY Upstate Medical University | United States

Author Profile

Scopus

ORCID Id

🩺Ghanshyam Ghelani, MD 💉

Hematology-Oncology Fellow & Clinical Investigator
SUNY Upstate Medical University, Syracuse, NY

🎓 Education

  • M.B.B.S. – B.J. Medical College, Ahmedabad, Gujarat, India (09/2002 – 03/2008)
    📚 Ranked in the top 10% of a class of 250 students.
  • Internal Medicine Residency – The Wright Center for Graduate Medical Education, Scranton, PA, USA (07/2013 – 06/2016)
    🏥 Completed residency at affiliate hospitals including Geisinger CMC and VA Medical Center.
    🏅 Awarded M.D. by New York State on November 16, 2016.
  • Hematology-Oncology Fellowship – SUNY Upstate Medical University, Syracuse, NY (07/2021 – 06/2024)
    💉 Active Member of the Transfusion Medicine Committee and Hematology-Oncology Representative of the Resident and Fellow Forum.

💼 Certifications and Licensure

  • Board Certification – The American Board of Internal Medicine
  • State License – New York: Full License # 285166
  • DEA Registration – FG6123385
  • Advanced Cardiac Life Support (ACLS) – Re-Certified on 10/09/2021

🌐 Professional Memberships

  • 👨‍⚕️ Member, American College of Physicians
  • 🇮🇳 Life Member, Gujarat Medical Council
  • 🩺 Member, American Medical Association (AMA)
  • 🧬 Member, American Society of Clinical Oncology (ASCO)
  • 🌍 Member, European Society for Medical Oncology (ESMO)
  • 🩸 Member, American Society of Hematology (ASH)

🔬 Research and Academic Work

Assistant Professor of Medicine & Clinical Investigator
SUNY Upstate Medical University (07/2016 – 06/2021)

  • Key Research Projects
    • 🧬 HPV-Positive Clinically Advanced Bladder Squamous Cell Carcinoma (aBSCC): Analyzed genomic alterations associated with HPV.
    • 🧑‍🔬 Metabolic Syndrome & Immunotherapy in NSCLC: Studied the impact of metabolic syndrome on outcomes with immune checkpoint inhibitors in non-small cell lung cancer (NSCLC).
    • 🩸 Peripheral Blood Biomarkers in Metastatic Melanoma: Identified biomarkers for treatment response and immune-related adverse events in patients treated with immunotherapy for stage-IV melanoma.

🏅 Awards

  • Ranked in the top 10% of the class during medical school. 🎖️

Dr. Ghanshyam Ghelani is a dedicated Hematology-Oncology fellow with expertise in internal medicine and a strong background in cancer research, particularly in genomic profiling, immunotherapy, and biomarker discovery. 🧬💡

 

🔍 Conclusion

Dr. Ghanshyam Ghelani is a highly accomplished medical professional, currently advancing his expertise as a Hematology-Oncology Fellow at SUNY Upstate Medical University. With a strong foundation in internal medicine and an impressive portfolio of research in cancer treatment and immunotherapy, Dr. Ghelani has made significant contributions to the field of oncology. His active involvement in professional societies and dedication to exploring novel cancer therapies highlight his commitment to improving patient outcomes through cutting-edge research and clinical practice. Dr. Ghelani’s journey reflects a deep passion for medicine, research, and innovation in cancer care. 💉🧬🌟

 

📊🔬NOTABLE PUBLICATION:

 

    • Radioimmunoconjugates in the Age of Modern Immuno-Oncology
      • Authors: Nasr, D., Kumar, P.A., Zerdan, M.B., Graziano, S., Lim, S.H.
      • Journal: Life Sciences
      • Year: 2022

     

    • HPV-Positive Clinically Advanced Squamous Cell Carcinoma of the Urinary Bladder (aBSCC): A Comprehensive Genomic Profiling (CGP) Study
      • Authors: Ghelani, G.H., Zerdan, M.B., Jacob, J., Bratslavsky, G., Basnet, A.
      • Journal: Urologic Oncology: Seminars and Original Investigations
      • Year: 2023

     

    • Breast Cancer Treatment: To Target or Not? That Is the Question
      • Authors: Stone, A., Lin, K.M., Ghelani, G.H., Graziano, S., Kotula, L.
      • Journal: Cancers
      • Year: 2023

     

    • Hematologic Abnormalities After COVID-19 Infection: A Case of Coombs-Negative Hemolytic Anemia and Thrombocytopenia
      • Authors: Siegenthaler, A.G., Ghelani, G., Brady, A., Loon, T., Madhira, B.R.
      • Journal: Journal of Investigative Medicine High Impact Case Reports
      • Year: 2023

     

    • Metabolic Syndrome Is Independently Associated with Improved Overall Survival to First-Line Therapy with Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
      • Authors: Bou Zerdan, M., Ashok Kumar, P., Barrios, D.M., Graziano, S., Lim, S.H.
      • Journal: Frontiers in Oncology
      • Year: 2023